Allogene Therapeutics Stock News

Investing in the technologies of tomorrow can be a lucrative investment strategy. If investors can discern trends as they develop, they can stay ahead of the curve and reap the rewards.

SOUTH SAN FRANCISCO, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloC

Allogene (ALLO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Allogene's (ALLO) fourth-quarter earnings beat estimates, but sales miss the mark. Management expects operating expenses for 2024 to be around $280 million.

Allogene Therapeutics (ALLO) came out with a quarterly loss of $0.43 per share versus the Zacks Consensus Estimate of a loss of $0.47. This compares to loss of $0.66 per share a year ago.

Allogene (ALLO) intends to combine its next generation AlloCAR T platform with Arbor Biotechnologies' proprietary CRISPR gene therapy technology to develop therapies for autoimmune diseases.

Allogene Therapeutics, Inc. (ALLO) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, ALLO's 50-day simple moving average broke out abo

Conference Call and Webcast Scheduled for March 14, 2024 at 2:00 p.m. PT/5:00 p.m. ET Conference Call and Webcast Scheduled for March 14, 2024 at 2:00 p.m. PT/5:00 p.m. ET

SOUTH SAN FRANCISCO, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCA

Allogene (ALLO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Allogene (ALLO) decides to deprioritize two pivotal studies for the third-line treatment of certain lymphoma patients and start a new study to focus on the first-line treatment of the indication.

Biotechnology company Allogene (NASDAQ: ALLO ) is certainly not having the day that many in the company's C-Suite may have anticipated. Shares of ALLO stock are plunging yet again, dropping more than

Allogene Therapeutics Inc (NASDAQ:ALLO) shares tumbled at the open Friday after the company revealed plans to cut 22% of its workforce, part of a strategic shift in pipeline prioritization and clinica

SOUTH SAN FRANCISCO, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCA

We present three small biotech stocks, which most analysts on Wall Street are optimistic about. These companies have upside potential for 2024 following signals of a stabilizing market.